中国癌症防治杂志
中國癌癥防治雜誌
중국암증방치잡지
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
2013年
4期
328-332
,共5页
朱建荣%万小蔹%崔小川%郁震
硃建榮%萬小蘞%崔小川%鬱震
주건영%만소렴%최소천%욱진
肺肿瘤%非小细胞肺癌%核苷酸切除修复交叉互补基因1%个体化治疗
肺腫瘤%非小細胞肺癌%覈苷痠切除脩複交扠互補基因1%箇體化治療
폐종류%비소세포폐암%핵감산절제수복교차호보기인1%개체화치료
Lung neoplasms%Non-small cell lung cancer%Excision repair cross-complementation group 1%Individualized therapy
目的:探讨转移淋巴结中核苷酸切除修复交叉互补基因1(excision repair cross-complementation group1,ERCC1)蛋白的表达情况,以指导非小细胞肺癌(non-small cell lung cancer,NSCLC)进行个体化治疗的价值。方法96例通过淋巴结病理组织检查确诊为NSCLC的患者,分为标准治疗组38例,选择含铂类药物的一线化疗方案化疗;个体化治疗组58例,根据转移淋巴结组织中ERCC1蛋白的表达情况选择个体化化疗方案治疗。分析比较两个治疗组的化疗效果,以Kaplan-Meier法分析两个治疗组患者生存期的差异。结果在患者转移淋巴结中ERCC1蛋白表达的阳性率为51.7%。个体化治疗组和标准治疗组的化疗有效率分别为58.6%和34.2%(P=0.019),两组的中位生存期分别为9个月和7个月,个体化治疗组的疗效明显优于标准治疗组(P=0.039)。结论检测淋巴结中ERCC1蛋白的表达以指导NSCLC个体化治疗可以提高化疗效果,延长患者的生存时间。
目的:探討轉移淋巴結中覈苷痠切除脩複交扠互補基因1(excision repair cross-complementation group1,ERCC1)蛋白的錶達情況,以指導非小細胞肺癌(non-small cell lung cancer,NSCLC)進行箇體化治療的價值。方法96例通過淋巴結病理組織檢查確診為NSCLC的患者,分為標準治療組38例,選擇含鉑類藥物的一線化療方案化療;箇體化治療組58例,根據轉移淋巴結組織中ERCC1蛋白的錶達情況選擇箇體化化療方案治療。分析比較兩箇治療組的化療效果,以Kaplan-Meier法分析兩箇治療組患者生存期的差異。結果在患者轉移淋巴結中ERCC1蛋白錶達的暘性率為51.7%。箇體化治療組和標準治療組的化療有效率分彆為58.6%和34.2%(P=0.019),兩組的中位生存期分彆為9箇月和7箇月,箇體化治療組的療效明顯優于標準治療組(P=0.039)。結論檢測淋巴結中ERCC1蛋白的錶達以指導NSCLC箇體化治療可以提高化療效果,延長患者的生存時間。
목적:탐토전이림파결중핵감산절제수복교차호보기인1(excision repair cross-complementation group1,ERCC1)단백적표체정황,이지도비소세포폐암(non-small cell lung cancer,NSCLC)진행개체화치료적개치。방법96례통과림파결병리조직검사학진위NSCLC적환자,분위표준치료조38례,선택함박류약물적일선화료방안화료;개체화치료조58례,근거전이림파결조직중ERCC1단백적표체정황선택개체화화료방안치료。분석비교량개치료조적화료효과,이Kaplan-Meier법분석량개치료조환자생존기적차이。결과재환자전이림파결중ERCC1단백표체적양성솔위51.7%。개체화치료조화표준치료조적화료유효솔분별위58.6%화34.2%(P=0.019),량조적중위생존기분별위9개월화7개월,개체화치료조적료효명현우우표준치료조(P=0.039)。결론검측림파결중ERCC1단백적표체이지도NSCLC개체화치료가이제고화료효과,연장환자적생존시간。
Objective To detect expression of excision repair cross-complementation group 1(ERCC1)protein in metastatic lymph nodes of patients with advanced non-small cell lung cancer (NSCLC),and investigate whether the expression can be useful for individualizing therapy. Methods A total of 96 patients with pathologically proven NSCLC involving lymph node metastasis were randomized between one group receiving standard treatment group(n=38),which was first-line platinum-based chemotherapy;and another group receiving individualized treatment(n=58),based on ERCC1 protein detection.Treatment effectiveness and Kaplan-Meier survival curves were compared between the two groups. Results ERCC1 protein was expressed in the metastatic lymph nodes of 51.7% of 58 cases.The response rate was significantly higher in the individualized treatment group(58.6%)than in the standard treatment group (34.2%,P=0.019),as was median overall survival (9 vs 7 months,P=0.039). Conclusions Individualized therapy based on ERCC1 protein detection in metastatic lymph nodes was associated with greater curative effect and survival than was standard therapy.